RxDoctor Payments Data

Glenda Buyo, MD

Family Medicine · Plantation, FLNPI 1841467883

Payments from drug & device makers

$1,384in general payments, 2019–2025

Across 41 payments — averaging $33.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$525
  • Astellas Pharma US Inc$321
  • Novartis$156
  • GSK$113
  • Sunovion Pharmaceuticals Inc.$76
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$64
  • plus $129 from 5 others

What the payments were for

  • Food & beverage$1,10480%
  • Education$28020%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,384 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$10,513
Medicare patients
35
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$106,755
EliquisApixaban81$90,760
XareltoRivaroxaban29$39,037
MyrbetriqMirabegron36$38,082
XifaxanRifaximin12$37,644
JanuviaSitagliptin Phosphate18$19,950
JardianceEmpagliflozin11$19,158
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$5,826
Atorvastatin Calcium659$5,329
LantusInsulin Glargine,hum.Rec.Anlog24$5,238
Losartan Potassium386$3,701
Levothyroxine Sodium233$2,693
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,310
Omeprazole278$2,294
Rosuvastatin Calcium216$2,195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$90,76081 claims
Johnson & JohnsonXarelto$34$39,03729 claims
Astellas Pharma US IncMyrbetriq$321$38,08236 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$64$37,64412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →